Published in
Esmo Open, Esmo Open, 1(5), p. e000638, 2020
DOI: 10.1136/esmoopen-2019-000638
Links
Tools
Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study
Journal article published in 2020 by
David Lau 
,
Eleftheria Kalaitzaki,
David N. Church,
Hardev Pandha,
Ian Tomlinson,
Nicola Annels,
Marco Gerlinger ,
Francesco Sclafani,
Gillian Smith,
Ruwaida Begum,
Richard Crux,
Angela Gillbanks,
Sarah Wordsworth,
Ian Chau,
Naureen Starling
and other authors.
,
Eleftheria Kalaitzaki,
David N. Church,
Hardev Pandha,
Ian Tomlinson,
Nicola Annels,
Marco Gerlinger ,
Francesco Sclafani,
Gillian Smith,
Ruwaida Begum,
Richard Crux,
Angela Gillbanks,
Sarah Wordsworth,
Ian Chau,
Naureen Starling
and other authors.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
Full text: Unavailable
Data provided by 